CDIO Cardio Diagnostics Holdings, Inc.
Healthcare$1.61+6.62%ClosedMarket Cap: $3.3M
As of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.51
P/S
201.25
EV/EBITDA
0.51
DCF Value
$2.29
FCF Yield
-182.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
-471.4%
Operating Margin
-40074.6%
Net Margin
-40152.5%
ROE
-78.8%
ROA
-69.6%
ROIC
-70.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $2.7K | $-1.8M | $— |
| Q4 null | $3.6K | $-1.5M | $— |
| FY null | $14.8K | $-6.5M | $— |
| Q3 null | $2.9K | $-1.7M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Trading Activity
Insider Trades
View AllIntrater Jamesdirector
SellThu Apr 02
Fung Peter Kdirector
SellThu Apr 02
Burton Paul Frederickdirector
SellThu Apr 02
Betts Wendy Jdirector
SellThu Apr 02
Intrater Jamesdirector
SellTue Jan 06
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.26
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.